The study, published in Cancer, found a 14% higher rate of obesity among childhood cancer survivors in their surveyed population, compared to the federal numbers.
Childhood cancer survivors - especially those whose treatment included brain irradiation or chemotherapy with glucocorticoids - are 14% more likely to be obese than their healthy peers. The St. Jude Children's Research Hospital study appears today in the journal Cancer.
Of the 1996 childhood cancer survivors in this study, 36.2% had a body mass index (BMI) of 30 kilograms per meters squared or more, which qualifies as obese. That was 14% greater than the expected prevalence based on federal health survey data of a comparison group of US residents. Among the strongest predictor of obesity in survivors was childhood obesity, which is also a strong predictor of adult obesity in the general public. Survivors who were obese when their pediatric cancer was discovered were almost 5 times more likely than other survivors to be obese when their BMI was calculated for this study.
Complete report on MedicalXpress: http://bit.ly/1JTe3ge
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More